Barclays Maintains an 'Overweight' on Chevron (CVX); Strong 3Q11 Results, Profitable Growth Outlook on Track
Get Alerts CVX Hot Sheet
Price: $205.77 --0%
Rating Summary:
27 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
27 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Chevron (NYSE: CVX) price target raised from $135 to $138.
Barclays analyst says, "CVX has been our favorite among the mega cap integrated oil companies due to its higher oil price leverage and relative valuation. The company's latest 3Q result has reinforced our belief. We estimate that CVX earned $25.9/boe in the quarter, $4.6/boe higher than its next closest competitor XOM, and ranking it as #1 among the super majors. Since 3Q09, the company has consistently ranked as one of the best in this metric with an average premium of $5.0/boe over the group's average."
For more ratings news on Chevron click here and for the rating history of Chevron click here.
Shares of Chevron closed at $109.64 yesterday.
Barclays analyst says, "CVX has been our favorite among the mega cap integrated oil companies due to its higher oil price leverage and relative valuation. The company's latest 3Q result has reinforced our belief. We estimate that CVX earned $25.9/boe in the quarter, $4.6/boe higher than its next closest competitor XOM, and ranking it as #1 among the super majors. Since 3Q09, the company has consistently ranked as one of the best in this metric with an average premium of $5.0/boe over the group's average."
For more ratings news on Chevron click here and for the rating history of Chevron click here.
Shares of Chevron closed at $109.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron (CVX) PT Raised to $218 at Morgan Stanley
- Raymond James Starts Southern California Bancorp (BCAL) at Outperform
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share